FDA Sets Regulatory Review Period for Aurora EV-ICD Patent Extension
February 06, 2026
February 06, 2026
WASHINGTON, Feb. 6 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced the determination of the regulatory review period for the Aurora EV-ICD medical device. This action follows applications submitted by Medtronic Inc. to the U.S. Department of Commerce Patent and Trademark Office seeking to extend the term of patents associated with this technology.
Aurora EV-ICD is an extravascular implantable cardioverter defibrillator. It provides . . .
Aurora EV-ICD is an extravascular implantable cardioverter defibrillator. It provides . . .